S&P 500   4,455.48 (+0.15%)
DOW   34,798.00 (+0.10%)
QQQ   373.40 (+0.11%)
AAPL   146.96 (+0.09%)
MSFT   299.53 (-0.01%)
FB   353.15 (+2.08%)
GOOGL   2,845.99 (+0.77%)
TSLA   774.14 (+2.72%)
AMZN   3,425.26 (+0.27%)
NVDA   220.50 (-1.92%)
BABA   145.08 (-4.04%)
NIO   35.38 (-1.75%)
CGC   13.90 (-4.53%)
GE   103.81 (+0.83%)
MU   74.02 (-0.03%)
AMD   105.76 (-0.37%)
T   27.12 (-0.26%)
F   13.76 (+0.36%)
ACB   5.96 (-3.09%)
DIS   176.00 (-0.14%)
PFE   43.97 (-0.50%)
BA   221.39 (+0.13%)
BAC   42.14 (+1.08%)
S&P 500   4,455.48 (+0.15%)
DOW   34,798.00 (+0.10%)
QQQ   373.40 (+0.11%)
AAPL   146.96 (+0.09%)
MSFT   299.53 (-0.01%)
FB   353.15 (+2.08%)
GOOGL   2,845.99 (+0.77%)
TSLA   774.14 (+2.72%)
AMZN   3,425.26 (+0.27%)
NVDA   220.50 (-1.92%)
BABA   145.08 (-4.04%)
NIO   35.38 (-1.75%)
CGC   13.90 (-4.53%)
GE   103.81 (+0.83%)
MU   74.02 (-0.03%)
AMD   105.76 (-0.37%)
T   27.12 (-0.26%)
F   13.76 (+0.36%)
ACB   5.96 (-3.09%)
DIS   176.00 (-0.14%)
PFE   43.97 (-0.50%)
BA   221.39 (+0.13%)
BAC   42.14 (+1.08%)
S&P 500   4,455.48 (+0.15%)
DOW   34,798.00 (+0.10%)
QQQ   373.40 (+0.11%)
AAPL   146.96 (+0.09%)
MSFT   299.53 (-0.01%)
FB   353.15 (+2.08%)
GOOGL   2,845.99 (+0.77%)
TSLA   774.14 (+2.72%)
AMZN   3,425.26 (+0.27%)
NVDA   220.50 (-1.92%)
BABA   145.08 (-4.04%)
NIO   35.38 (-1.75%)
CGC   13.90 (-4.53%)
GE   103.81 (+0.83%)
MU   74.02 (-0.03%)
AMD   105.76 (-0.37%)
T   27.12 (-0.26%)
F   13.76 (+0.36%)
ACB   5.96 (-3.09%)
DIS   176.00 (-0.14%)
PFE   43.97 (-0.50%)
BA   221.39 (+0.13%)
BAC   42.14 (+1.08%)
S&P 500   4,455.48 (+0.15%)
DOW   34,798.00 (+0.10%)
QQQ   373.40 (+0.11%)
AAPL   146.96 (+0.09%)
MSFT   299.53 (-0.01%)
FB   353.15 (+2.08%)
GOOGL   2,845.99 (+0.77%)
TSLA   774.14 (+2.72%)
AMZN   3,425.26 (+0.27%)
NVDA   220.50 (-1.92%)
BABA   145.08 (-4.04%)
NIO   35.38 (-1.75%)
CGC   13.90 (-4.53%)
GE   103.81 (+0.83%)
MU   74.02 (-0.03%)
AMD   105.76 (-0.37%)
T   27.12 (-0.26%)
F   13.76 (+0.36%)
ACB   5.96 (-3.09%)
DIS   176.00 (-0.14%)
PFE   43.97 (-0.50%)
BA   221.39 (+0.13%)
BAC   42.14 (+1.08%)
NASDAQ:DBVT

DBV Technologies Stock Forecast, Price & News

$4.92
-0.14 (-2.77 %)
(As of 09/24/2021 03:23 PM ET)
Add
Compare
Today's Range
$4.92
$5.15
50-Day Range
$4.71
$5.92
52-Week Range
$1.35
$7.38
Volume1,997 shs
Average Volume294,223 shs
Market Capitalization$541.31 million
P/E RatioN/A
Dividend YieldN/A
Beta2.6
30 days | 90 days | 365 days | Advanced Chart
Receive DBVT News and Ratings via Email

Sign-up to receive the latest news and ratings for DBV Technologies and its competitors with MarketBeat's FREE daily newsletter.


DBV Technologies logo

About DBV Technologies

DBV Technologies SA is a clinical-stage biopharmaceutical company, which engages in the research and development of epicutaneous immunotherapy products. The firm focuses on the development of Viaskin, an electrostatic patch, which may offer a convenient, self-administered, and non-invasive immunotherapy to patients. It also designs a robust clinical development program that includes ongoing clinical trials of Viaskin peanut, and Viaskin milk, as well as pre-clinical development of Viaskin egg. The company was founded by Pierre-Henri Benhamou, Stéphane Benhamou, Bertrand Dupont, Christophe Dupont, and Pierre-Yves Vannerom on March 29, 2002 and is headquartered in Montrouge, France.

Headlines

DBV Technologies (NASDAQ:DBVT) Shares Gap Up to $4.94
DBV Technologies (NASDAQ:DBVT) Shares Gap Up to $4.94
September 15, 2021 |  americanbankingnews.com
DBV Technologies (NASDAQ:DBVT) Lifted to "Buy" at Societe Generale
DBV Technologies (NASDAQ:DBVT) Lifted to "Buy" at Societe Generale
September 14, 2021 |  americanbankingnews.com
DBV Technologies (NASDAQ:DBVT) Sees Strong Trading Volume
DBV Technologies (NASDAQ:DBVT) Sees Strong Trading Volume
September 14, 2021 |  americanbankingnews.com
DBV Technologies (NASDAQ:DBVT) Shares Gap Down to $5.24
DBV Technologies (NASDAQ:DBVT) Shares Gap Down to $5.24
September 13, 2021 |  americanbankingnews.com
DBV Technologies (NASDAQ:DBVT) Shares Gap Down to $5.67
DBV Technologies (NASDAQ:DBVT) Shares Gap Down to $5.67
September 7, 2021 |  americanbankingnews.com
DBV Technologies (NASDAQ:DBVT) Shares Gap Down to $5.92
DBV Technologies (NASDAQ:DBVT) Shares Gap Down to $5.92
September 1, 2021 |  americanbankingnews.com
DBV Technologies (NASDAQ:DBVT) Trading Up 5.4%
DBV Technologies (NASDAQ:DBVT) Trading Up 5.4%
August 31, 2021 |  americanbankingnews.com
See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

1.68 out of 5 stars

Medical Sector

930th out of 1,351 stocks

Biological Products, Except Diagnostic Industry

145th out of 193 stocks

Analyst Opinion: 3.5Community Rank: 4.3Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











DBV Technologies (NASDAQ:DBVT) Frequently Asked Questions

Is DBV Technologies a buy right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for DBV Technologies in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" DBV Technologies stock.
View analyst ratings for DBV Technologies
or view top-rated stocks.

What stocks does MarketBeat like better than DBV Technologies?

Wall Street analysts have given DBV Technologies a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but DBV Technologies wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting DBV Technologies?

DBV Technologies saw a decrease in short interest in the month of August. As of August 31st, there was short interest totaling 1,090,000 shares, a decrease of 35.9% from the August 15th total of 1,700,000 shares. Based on an average trading volume of 54,700 shares, the days-to-cover ratio is currently 19.9 days. Currently, 1.0% of the shares of the company are sold short.
View DBV Technologies' Short Interest
.

How were DBV Technologies' earnings last quarter?

DBV Technologies S.A. (NASDAQ:DBVT) posted its quarterly earnings results on Sunday, August, 1st. The company reported ($0.28) earnings per share for the quarter, beating analysts' consensus estimates of ($0.64) by $0.36. The business had revenue of ($1.49) million for the quarter, compared to analysts' expectations of $3.53 million.
View DBV Technologies' earnings history
.

How has DBV Technologies' stock been impacted by Coronavirus?

DBV Technologies' stock was trading at $7.08 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, DBVT stock has decreased by 30.5% and is now trading at $4.92.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for DBVT?

3 brokers have issued 12 month price objectives for DBV Technologies' stock. Their forecasts range from $7.00 to $8.00. On average, they anticipate DBV Technologies' stock price to reach $7.50 in the next twelve months. This suggests a possible upside of 52.4% from the stock's current price.
View analysts' price targets for DBV Technologies
or view top-rated stocks among Wall Street analysts.

Who are DBV Technologies' key executives?

DBV Technologies' management team includes the following people:
  • Daniel Tassé, Chief Executive Officer & Executive Director
  • Sébastien Robitaille, Chief Financial Officer
  • Pharis Mohideen, Chief Medical Officer
  • Pascal Wotling, Chief Technical Operations Officer
  • Pascale Ehouarn, Chief Engineering, Manufacturing & Supply Officer

What other stocks do shareholders of DBV Technologies own?

Based on aggregate information from My MarketBeat watchlists, some companies that other DBV Technologies investors own include Aimmune Therapeutics (AIMT), OPKO Health (OPK), Bellicum Pharmaceuticals (BLCM), Axsome Therapeutics (AXSM), Gilead Sciences (GILD), Novavax (NVAX), AbbVie (ABBV), Pieris Pharmaceuticals (PIRS), Pfizer (PFE) and Sangamo Therapeutics (SGMO).

What is DBV Technologies' stock symbol?

DBV Technologies trades on the NASDAQ under the ticker symbol "DBVT."

Who are DBV Technologies' major shareholders?

DBV Technologies' stock is owned by a variety of retail and institutional investors. Top institutional investors include Morgan Stanley (1.34%), Morgan Stanley (1.34%), ArrowMark Colorado Holdings LLC (1.30%), Millennium Management LLC (0.71%), Nan Fung Group Holdings Ltd (0.26%) and Premier Asset Management LLC (0.14%).

Which major investors are selling DBV Technologies stock?

DBVT stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, Morgan Stanley, Morgan Stanley, Bank of America Corp DE, Marshall Wace North America L.P., ArrowMark Colorado Holdings LLC, Personal CFO Solutions LLC, and Group One Trading L.P..

Which major investors are buying DBV Technologies stock?

DBVT stock was acquired by a variety of institutional investors in the last quarter, including Nan Fung Group Holdings Ltd, Premier Asset Management LLC, Citadel Advisors LLC, DCM Advisors LLC, Geode Capital Management LLC, and Parametric Portfolio Associates LLC.

How do I buy shares of DBV Technologies?

Shares of DBVT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is DBV Technologies' stock price today?

One share of DBVT stock can currently be purchased for approximately $4.92.

How much money does DBV Technologies make?

DBV Technologies has a market capitalization of $541.31 million and generates $11.28 million in revenue each year. The company earns $-159,550,000.00 in net income (profit) each year or ($1.26) on an earnings per share basis.

How many employees does DBV Technologies have?

DBV Technologies employs 142 workers across the globe.

What is DBV Technologies' official website?

The official website for DBV Technologies is www.dbv-technologies.com.

Where are DBV Technologies' headquarters?

DBV Technologies is headquartered at 177-181 AVENUE PIERRE BROSSOLETTE, MONTROUGE I0, 92120.

How can I contact DBV Technologies?

DBV Technologies' mailing address is 177-181 AVENUE PIERRE BROSSOLETTE, MONTROUGE I0, 92120. The company can be reached via phone at (315) 542-7878 or via email at [email protected].


This page was last updated on 9/24/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.